摘要:

The influence of adjuvant chemotherapy (ACT) for operable breast cancer on the results of systemic therapy at relapse was retrospectively studied in 62 patients with recurrent disease. 32 had been treated with ACT [ACT (+) group] and the others had not [ACT (–) group]. The response rate (CR + PR) to the first treatment was 22% in the ACT (+) group and 43% in ACT (–) group. It is suggested that relapsing patients with a history of ACT respond poorly to the treatment as compared to those not receiving

ISSN:0030-2414    

DOI:10.1159/000226687

出版商:S. Karger AG    

年代:1989

数据来源: Karger

摘要:

From 1976 to 1984, 135 recurrent breast cancer patients were treated with chemotherapy and/or additive endocrine therapy and their initial therapies and survival time were analyzed. Survival from the time of recurrence in these patients was longer than historical control patients (median 26 vs. 14 months). There was no statistical difference amongst the four groups which were subdivided by initial therapies after recurrence (tamoxifen alone, tamofixen + tegafur, tamoxifen + other chemotherapy and chemotherapy). Therefore, the type of initial therapy did not affect the survival among these patients.

ISSN:0030-2414    

DOI:10.1159/000226688

出版商:S. Karger AG    

年代:1989

数据来源: Karger

摘要:

To evaluate the influence of delay between first symptom and first treatment upon survival the medical records of 596 patients with breast cancer were reviewed. The following intervals were considered: 6 months. Patients in the <3 months delay group had a better distribution by clinical stages and a 10-year survival rate higher than those in the longer delay groups (p = 0.034). However, within each stage no statistically significant difference in survival according to delay was observed. A Cox multivariate analysis revealed that performance status and stage of disease were independent predictors of survival, but not delay. Assuming the best prognosis for patients with clinical stages I and II and <3 months delay, the group with longer delay times had 15 deaths over what would have been predicted. This adverse effect was observed almost exclusively among patients over age 50 (14/15

ISSN:0030-2414    

DOI:10.1159/000226689

出版商:S. Karger AG    

年代:1989

数据来源: Karger

摘要:

Forty-four patients with advanced gastric adenocarcinoma were treated with the fluorouracil, adriamycin and mitomycin-C (FAM) regimen. One was excluded from response evaluation. Partial (PR) and minor (MR) response rates were 7 and 9% respectively. These patients enjoyed remission for a median of 7.0 months. Stabilization (S) occurred in 25% and lasted a median of 6.0 months. No response (NR) was associated with a median survival of 3 months (p <0.001). The predominant pretreatment factors to affect survival were diagnosis to treatment interval and initial CEA serum level. Performance status influenced survival less markedly. Toxicity was mainly myelosuppression, which resulted in death of one patient. ‘Responders’ had marrow suppression more frequently than NR. Comparison of PR + MR, PR + MR + S and NR patient groups showed median minimum WBC counts of 1.4 × 103, 2.6 × 103 and 4.3 × 103 per mm3 respectively. Leukopenia (<3,000/mm3) was associated with a median survival advantage of 9.5 versus 3.5 months (p <0.05) and did not depend significantly on given FAM dosage. The median dosage of FAM agents delivered to nonresponders was reduced. A trend of dose-response (including dose-survival) relationship was found but was inconclusive statist

ISSN:0030-2414    

DOI:10.1159/000226690

出版商:S. Karger AG    

年代:1989

数据来源: Karger

摘要:

Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals. Two patients had a partial response (6%) and 14 a stable disease (47%). The toxicity of this regimen was essentially digestive with 30% of grade 3 or 4 nausea and vomiting. In spite of the reported active and synergistic action of drug association in colorectal carcinoma, this treatment schedule is not better than 5-FU alone. Moreover, gastrointestinal toxicity is increased.

ISSN:0030-2414    

DOI:10.1159/000226691

出版商:S. Karger AG    

年代:1989

数据来源: Karger

摘要:

Eighty-five patients with small cell lung cancer (limited disease = LD in 39, extensive disease = ED in 46) received the combination of cyclophosphamide, methotrexate, vincristine and CCNU, and mediastinal radiotherapy given simultaneously after the third course of chemotherapy. The duration of treatment was approximately 12 months. A complete response was obtained in 41% of LD and in 15% of ED patients, and a partial response in 38 and 22%, respectively. Median survival was 55 weeks for LD and 37 weeks for ED patients. Two patients (5%) with LD have survived free of disease more than 3 years since their diagnosis.

ISSN:0030-2414    

DOI:10.1159/000226692

出版商:S. Karger AG    

年代:1989

数据来源: Karger

摘要:

A pilot study was undertaken to evaluate toxicity and activity of recombinant alpha-2b interferon in patients with metastatic malignant melanoma. Interferon was administered at the dosage of 10 × 106 IU/m2, 3 times a week i.m. 21 patients entered the study, 17 pretreated with chemotherapy and/or immunotherapy and 6 untreated. We obtained 3 partial responses (14.3%; 95% CL, 3.0–36.3%); 9 patients had stable disease. All patients experienced flue-like symptoms and fever; most fatigue and worsening of performance status. Recombinant interferon alpha-2b at the dosage and schedule used has limited but definite activity in metastatic malignant melanoma; the substantial subjective toxicity must be taken into consideration. Further trials testing recombinant alpha interferon in combination with chemoterapeutic agents, like DTIC, are warrant

ISSN:0030-2414    

DOI:10.1159/000226693

出版商:S. Karger AG    

年代:1989

数据来源: Karger

摘要:

The highly differentiated thyroid tumours account for 0.80% of all human malignancies. The papillary and follicular tumour tissues of this tumour type are relatively benign, hormone-dependent and beside their treatment specificity they secrete the tumour-specific thyroglobulin. This it becomes possible to follow the development of metastases, the effectiveness of therapy applied as well as the history of the disease. The authors studied the change of thyroglobulin level in 153 patients with highly differentiated thyroid cancer. In 29 of 32 metastatic patients a pathologically elevated (70–100 ng/ml) thyroglobulin level was observed. This proves the 91% specificity of the method in verified metastatic tumours. Compared to the total body scintigraphy 3 false-negative and 6 false-positive cases were found. The authors establish that, irrespective of the site of metastasis, the thyroglobulin level is higher in the follicular than in the papillary subtype. It is concluded that the measurement of the serum thyroglobulin level is a suitable marker of the highly differentiated thyroid cancer since it indicates local recurrence or distant metastases by a significant increase while therapy-resultant tumour diminution is accompanied by a marked decreas

ISSN:0030-2414    

DOI:10.1159/000226694

出版商:S. Karger AG    

年代:1989

数据来源: Karger

摘要:

A double-blind randomized cross-over trial of dexamethasone and prochlorperazine as adjunctive anti-emetics with cancer chemotherapy was undertaken. The drugs were compared for cisplatin, doxorubicin and several other chemotherapy regimens. A total of 44 eligible patients were analysed. Assessment was made by questionnaire answered by the patient 24 h after the chemotherapy. The parameters compared were period of time for nausea and vomiting, number of vomiting episodes, degree of somnolence and insomnia and overall preference. In all cases there was no significant difference for either drug in its ability to suppress emetic effects. Neither drug gave adequate protection against cisplatin-containing regimens. We conclude that dexamethaxone alone is equivalent to the more standard dopamine antagonists.

ISSN:0030-2414    

DOI:10.1159/000226695

出版商:S. Karger AG    

年代:1989

数据来源: Karger

摘要:

Eighty-nine patients with advanced ovarian cancer have been treated with a combination of cis-platinum (50 mg/m2) + an anthracycline (adriamycin 50 mg/m2 in 26 patients, or epirubicin 60 mg/m2 in 63 patients). The treatment was repeated every 28 days for a maximum of 12 cycles. Seventy-nine were evaluable for response. CR was achieved in 19 (24%) patients (2 clinical and 17 after a second-look evaluation) and a PR in 31 (39%) for an estimated median duration of 43 and 10 months, respectively. Nine patients who achieved CR and 2 out of 10 non-evaluable patients were alive without any evidence of disease after a median follow-up of 36 months (range 29–53). The treatment was generally well tolerated. The multivariate actuarial 4-year analysis by Cox’s proportional hazards model shows that residual tumor and performance status have an independent prognostic value on survival. The combination of CP + an anthracycline (and in particular epirubicin) is an effective and generally well tolerated treatment for ovarian cancer. Only patients with initial minimal residual disease and achieving CR are candidates for long-term survi

ISSN:0030-2414    

DOI:10.1159/000226696

出版商:S. Karger AG    

年代:1989

数据来源: Karger